drug
Euthyrox
Marketedupdated 3mo agoby EMD Serono Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- druglevothyroxine sodium42 co-mentions · 37 sources
- drugLevoxyl41 co-mentions · 37 sources
- drugTirosint40 co-mentions · 37 sources
- drugLevolet40 co-mentions · 37 sources
- drugErmeza40 co-mentions · 37 sources
- tagRecall38 co-mentions · 37 sources
- companyAccord Healthcare Inc28 co-mentions · 13 sources
- companyMylan Pharmaceuticals Inc19 co-mentions · 19 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 1 investigational indication.
all catalysts(0)
nothing on the calendar yet
Trials studying Euthyrox
- phase4Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH)
- phase2Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism
- phase1Fasting Study of Levothyroxine Sodium Tablets 300 mcg to Synthroid® Tablets 300 mcg
- phase1Fasting Study of Levothyroxine Sodium Tablets 300 μg to Levothroid® Tablets 300 μg
- phase1Fasting Study of Levothyroxine Sodium Tablets 300 μg to Synthroid® Tablets 300 μg
- phase1Fasting Study of Levothyroxine Sodium Tablets 200 mg to Synthroid Tablets 200 mg
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 6, 2031
~5.0 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (116)
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 26, 2044formulationUS 12564565
- Sep 17, 2039method-of-use (U-3757)US 11241382
- Sep 17, 2039method-of-use (U-3757)US 11241382
- Sep 17, 2039method-of-use (U-3757)US 11241382
- Sep 17, 2039method-of-use (U-3757)US 11241382
- Sep 17, 2039method-of-use (U-3757)US 11241382
- Sep 17, 2039method-of-use (U-3757)US 11241382
- Sep 17, 2039method-of-use (U-3758)US 11241382
- Sep 17, 2039method-of-use (U-3757)US 11241382
- Sep 17, 2039method-of-use (U-3757)US 11241382
- Sep 17, 2039method-of-use (U-3757)US 11241382
- Sep 17, 2039method-of-use (U-3757)US 11241382
- Sep 17, 2039method-of-use (U-3757)US 11241382
- Sep 17, 2039method-of-use (U-3757)US 11241382
- Sep 17, 2039method-of-use (U-3757)US 11241382
- Sep 17, 2039method-of-use (U-3757)US 11241382
- Mar 23, 2038formulationUS 10231931
- Mar 23, 2038formulationUS 10231931
- Mar 23, 2038formulationUS 10231931
- Mar 23, 2038formulationUS 10231931
- Mar 23, 2038formulationUS 10231931
- Mar 23, 2038formulationUS 10231931
- Mar 23, 2038formulationUS 10231931
- Mar 23, 2038formulationUS 10231931
- Mar 23, 2038formulationUS 10231931
- Mar 23, 2038formulationUS 10231931
- Mar 23, 2038formulationUS 10406108
- Mar 23, 2038formulationUS 10406108
- Mar 23, 2038formulationUS 10406108
- Mar 23, 2038formulationUS 10406108
- Mar 23, 2038formulationUS 10406108
- Mar 23, 2038formulationUS 10406108
- Mar 23, 2038formulationUS 10406108
- Mar 23, 2038formulationUS 10406108
- Mar 23, 2038formulationUS 10406108
- Mar 23, 2038formulationUS 10406108
- Feb 28, 2037formulationUS 10537538
- Feb 28, 2037formulationUS 10537538
- Feb 28, 2037formulationUS 10537538
- Feb 28, 2037formulationUS 10537538
- Feb 28, 2037formulationUS 10537538
- Feb 28, 2037formulationUS 10537538
- Feb 28, 2037formulationUS 10537538
- Feb 28, 2037formulationUS 10537538
- Feb 28, 2037formulationUS 10537538
- Feb 28, 2037formulationUS 10537538
- Feb 28, 2037formulationUS 10537538
- Feb 28, 2037formulationUS 10537538
- Feb 28, 2037formulationUS 10537538
- Feb 28, 2037formulationUS 10537538
- Feb 28, 2037formulationUS 10537538
- Feb 28, 2037formulationUS 11096913
- Feb 28, 2037formulationUS 11096913
- Feb 28, 2037formulationUS 11096913
- Feb 28, 2037formulationUS 11096913
- Feb 28, 2037formulationUS 11096913
- Feb 28, 2037formulationUS 11096913
- Feb 28, 2037formulationUS 11096913
- Feb 28, 2037formulationUS 11096913
- Feb 28, 2037formulationUS 11096913
- Feb 28, 2037formulationUS 11096913
- Feb 28, 2037formulationUS 11096913
- Feb 28, 2037formulationUS 11096913
- Feb 28, 2037formulationUS 11096913
- Feb 28, 2037formulationUS 11096913
- Feb 28, 2037formulationUS 11096913
- Dec 1, 2036formulationUS 10398669
- Dec 1, 2036formulationUS 10398669
- Dec 1, 2036formulationUS 10398669
- Dec 1, 2036formulationUS 11135190
- Dec 1, 2036formulationUS 11135190
- Dec 1, 2036formulationUS 11135190
- Dec 1, 2036formulationUS 9782376
- Dec 1, 2036formulationUS 9782376
- Dec 1, 2036formulationUS 9782376
- Jul 20, 2036formulationUS 11154498
- Feb 27, 2035formulationUS 9345772
- Oct 3, 2032formulationUS 9006289
- Oct 3, 2032formulationUS 9006289
- Oct 3, 2032formulationUS 9006289
- Aug 29, 2032formulationUS 9168238
- Aug 29, 2032formulationUS 9168238
- Aug 29, 2032formulationUS 9168238
- Aug 29, 2032formulationUS 9168239
- Aug 29, 2032formulationUS 9168239
- Aug 29, 2032formulationUS 9168239
- Aug 6, 2031formulationUS 90503075.0y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 48m ago
Found something off?
comments(0)
5-min edit window · permanent after that